PHARMACOLOGY EXAM PACK:
COMPREHENSIVE QUESTION
BANK (2026 Edition)|| Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Instructions: Choose the best answer for each question. Correct answers
are highlighted in bold. Rationales are provided after each answer set.
SECTION A: GENERAL PRINCIPLES OF PHARMACOLOGY (Q1–Q15)
1. A drug with a high therapeutic index is:
• A) Likely to cause toxicity at therapeutic doses
• B) Relatively safe with a wide margin between effective and toxic doses
• C) Requires strict therapeutic drug monitoring
• D) Has a steep dose-response curve
Rationale: High therapeutic index = large safety margin. Low TI drugs (e.g.,
digoxin, warfarin) need monitoring.
2. First-pass effect refers to:
• A) Rapid distribution from blood to tissues
• B) Extensive hepatic metabolism of an oral drug before reaching
systemic circulation
• C) Binding of drug to plasma proteins
• D) Excretion via glomerular filtration
,Rationale: Oral drugs absorbed from the gut pass via the portal vein to the liver,
where metabolism reduces bioavailability.
3. Which phase of drug metabolism typically involves conjugation reactions?
• A) Phase I (oxidation, reduction)
• B) Phase II (glucuronidation, acetylation)
• C) Phase 0 (dissolution)
• D) Phase III (elimination)
Rationale: Phase II adds polar groups to enhance renal excretion.
4. A drug with zero-order kinetics:
• A) Has a constant half-life regardless of dose
• B) Eliminates a constant amount per unit time
• C) Follows first-order elimination at high doses
• D) Is excreted mainly by glomerular filtration
Rationale: Example: Phenytoin, ethanol. Saturation of metabolic enzymes →
constant rate.
5. The volume of distribution (Vd) of a drug is 0.07 L/kg. This suggests:
• A) The drug is confined to plasma water
• B) The drug accumulates in fatty tissues
• C) The drug is extensively bound to tissue proteins
• D) The drug crosses the blood-brain barrier easily
Rationale: Vd ~0.05-0.1 L/kg suggests plasma compartment only (e.g., warfarin,
heparin).
6. A CYP450 enzyme inducer (e.g., rifampin) given with warfarin will likely
cause:
• A) Increased warfarin effect → bleeding risk
• B) Decreased warfarin effect → thrombosis risk
• C) No change in INR
, • D) Increased warfarin metabolism initially then inhibition
Rationale: Induction → faster warfarin metabolism → lower INR → reduced
anticoagulation.
7. The therapeutic window is defined as:
• A) Time to reach steady state
• B) Dose required for 50% of maximal effect
• C) Range of doses producing therapeutic response without toxicity
• D) Plasma concentration where receptor occupancy is 100%
8. Which drug characteristic allows once-daily dosing?
• A) Short half-life (1–2 hours)
• B) Long half-life (24+ hours)
• C) Rapid renal clearance
• D) High first-pass metabolism
9. Bioavailability of an intravenous drug is:
• A) Less than 100% due to protein binding
• B) 100% by definition
• C) Dependent on gastric pH
• D) Reduced in liver cirrhosis
10. A competitive antagonist:
• A) Binds irreversibly to the receptor
• B) Shifts the agonist dose-response curve to the right without reducing
maximum response
• C) Reduces the maximal efficacy of an agonist
• D) Is always an inverse agonist
11. The primary site of biotransformation for most drugs is:
• A) Kidney
COMPREHENSIVE QUESTION
BANK (2026 Edition)|| Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Instructions: Choose the best answer for each question. Correct answers
are highlighted in bold. Rationales are provided after each answer set.
SECTION A: GENERAL PRINCIPLES OF PHARMACOLOGY (Q1–Q15)
1. A drug with a high therapeutic index is:
• A) Likely to cause toxicity at therapeutic doses
• B) Relatively safe with a wide margin between effective and toxic doses
• C) Requires strict therapeutic drug monitoring
• D) Has a steep dose-response curve
Rationale: High therapeutic index = large safety margin. Low TI drugs (e.g.,
digoxin, warfarin) need monitoring.
2. First-pass effect refers to:
• A) Rapid distribution from blood to tissues
• B) Extensive hepatic metabolism of an oral drug before reaching
systemic circulation
• C) Binding of drug to plasma proteins
• D) Excretion via glomerular filtration
,Rationale: Oral drugs absorbed from the gut pass via the portal vein to the liver,
where metabolism reduces bioavailability.
3. Which phase of drug metabolism typically involves conjugation reactions?
• A) Phase I (oxidation, reduction)
• B) Phase II (glucuronidation, acetylation)
• C) Phase 0 (dissolution)
• D) Phase III (elimination)
Rationale: Phase II adds polar groups to enhance renal excretion.
4. A drug with zero-order kinetics:
• A) Has a constant half-life regardless of dose
• B) Eliminates a constant amount per unit time
• C) Follows first-order elimination at high doses
• D) Is excreted mainly by glomerular filtration
Rationale: Example: Phenytoin, ethanol. Saturation of metabolic enzymes →
constant rate.
5. The volume of distribution (Vd) of a drug is 0.07 L/kg. This suggests:
• A) The drug is confined to plasma water
• B) The drug accumulates in fatty tissues
• C) The drug is extensively bound to tissue proteins
• D) The drug crosses the blood-brain barrier easily
Rationale: Vd ~0.05-0.1 L/kg suggests plasma compartment only (e.g., warfarin,
heparin).
6. A CYP450 enzyme inducer (e.g., rifampin) given with warfarin will likely
cause:
• A) Increased warfarin effect → bleeding risk
• B) Decreased warfarin effect → thrombosis risk
• C) No change in INR
, • D) Increased warfarin metabolism initially then inhibition
Rationale: Induction → faster warfarin metabolism → lower INR → reduced
anticoagulation.
7. The therapeutic window is defined as:
• A) Time to reach steady state
• B) Dose required for 50% of maximal effect
• C) Range of doses producing therapeutic response without toxicity
• D) Plasma concentration where receptor occupancy is 100%
8. Which drug characteristic allows once-daily dosing?
• A) Short half-life (1–2 hours)
• B) Long half-life (24+ hours)
• C) Rapid renal clearance
• D) High first-pass metabolism
9. Bioavailability of an intravenous drug is:
• A) Less than 100% due to protein binding
• B) 100% by definition
• C) Dependent on gastric pH
• D) Reduced in liver cirrhosis
10. A competitive antagonist:
• A) Binds irreversibly to the receptor
• B) Shifts the agonist dose-response curve to the right without reducing
maximum response
• C) Reduces the maximal efficacy of an agonist
• D) Is always an inverse agonist
11. The primary site of biotransformation for most drugs is:
• A) Kidney
